Daily Stock List
Yappn Corp. (YPPN)
TopPennyStockMovers, SmallCapFinancialWire, PennyStocks24, Shiznit Stocks, MyBestStockAlerts, Fast Money Alerts, Penny Stock General, and Stock Shock and Awe reported earlier on Yappn Corp. (YPPN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Yappn Corp. is a real-time innovative language solutions company that amplifies brand messaging, helps conduct commerce, and provides customer support through globalizing these experiences with its proprietary approach to language. Yappn provides people and brands the power to be social, conduct commerce, and communicate freely without a language barrier. Yappn provides products for eCommerce, customer care, enhanced messaging collaboration, and online marketing.
Established in 2010, the Company has its U.S. headquarters in New York City and its Canadian headquarters in Markham, Ontario. It formerly went by the name Plesk Corp. It changed its name to Yappn Corp. in March 2013. The Company lists on the OTCQB.
Yappn also provides custom translation solutions to various verticals, such as entertainment, retail, and marketing. The Company has its new e-translation product, the Vendor Input Manager (VIM). This is an advanced product that provides worldwide vendors with the ability to integrate into top eCommerce marketplace sites.
Yappn is where people can meet, chat, engage, and consume content in 67 languages via the Company’s Real Time Multilingual Amplification platform. Yappn is free for users who want to participate on the Company’s general discussion board, unless otherwise noted.
A user’s language is detected by their browser setting automatically. At the very bottom of the page, a user will find a translator bar with the option to select numerous languages. A user chooses their language and all Yappn pages instantly translate. Yappn members can participate individually or in groups, regardless of the language they speak. Everything a person sees on Yappn is in their language, regardless of the language in which it was first posted.
Yappn has its international media and social sharing platform, FotoYapp, in major app stores for iPad ®, iPhones® and Android® devices. FotoYapp enables viewers and users globally to share images, video, and social comments in their native language, promoting Global Storytelling together with social networking sites in almost any language.
Yesterday, Yappn announced that it was awarded a contract for eCommerce Translation with Reebonz Limited. Reebonz is one of the most established online luxury companies in Southeast Asia. Yappn will first support four languages with an additional seven languages to be added later. The annual contract includes translation for the Reebonz.com main site and its marketplace site.
Yappn Corp. (YPPN), closed Wednesday's trading session at $0.132, up 32.00%, on 2,800 volume with 2 trades. The average volume for the last 60 days is 8,015 and the stock's 52-week low/high is $0.051/$0.75.
Propanc Health Group Corp. (PPCH)
Money Morning, Equities, PennyPro, Insider Financial, Ceocast News, PennyStocks24, Greenbackers, PennyStockRumors.net, PricelessPennyStocks, and Top Stock Picks reported on Propanc Health Group Corp. (PPCH), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Propanc Health Group Corp. is an Australian emerging healthcare company centering on the development of new and proprietary treatments for cancer patients, especially those suffering from pancreatic, ovarian and colorectal cancers. The Company has developed, with its scientific and oncology consultants, a rational, composite formulation of anti-cancer compounds that enable and support an assortment of cancer treatment options. Propanc’s leading products are variations upon its novel formulation and involve or employ proenzymes. These are inactive precursors of enzymes. Propanc Health Group lists on the OTCQB.
A development stage healthcare company, Propanc’s intention in the near term is to target patients with limited remaining therapeutic options for the treatment of solid tumors. This includes colorectal or pancreatic tumors. In the future, the Company’s plan is to develop its lead product to treat early stage cancer, pre-cancerous diseases, and as a preventative measure for patients at risk of developing cancer based on genetic screening.
Propanc’s leading products are PRP and PRP-DCM. These are novel, patented suppository formulations based on proteolytic proenzymes, which are inactive precursors of enzymes. PRP is a novel, patented, once daily suppository formulation of proteolytic proenzymes. PRP is a solution for once daily intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen.
Regarding PRP-DCM, work undertaken by Propanc has focused on maximizing the potential of PRP as a drug suitable for long term maintenance. Scientific research has concentrated on developing a novel combination of anti-cancer agents working in combination with proteolytic proenzymes that enhance PRP’s anti-cancer effects.
Many preclinical activities are underway for Propanc’s lead product, PRP. Animal efficacy studies in a number of tumor cell lines are underway for PRP with the Company’s research partner, vivoPharm, in Hershey, Pennsylvania. Also, Propanc has chosen pancreatic cancer as its lead indication for human studies. Company Management will seek Orphan Drug Designation for PRP for this indication in each jurisdiction.
Last month, Propanc Health Group announced the start of the in-life phase of the GLP-compliant, 28-day repeat-dose toxicity study for its lead product, PRP. The study is being conducted via Propanc's Partner CRO (Contract Research Organization), vivoPharm Pty Ltd, at their accredited laboratories in Melbourne, Australia.
This month, Propanc Health Group announced that it received a notification of allowance for its lead patent application from the US Patent Office. The patent application provides extensive coverage for a method of treating a solid tumor through administering a pharmaceutical composition consisting of a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients.
For 2017, Propanc Health Group expects to complete the GLP-compliant, 28-day repeat-dose toxicity study in rats for PRP; finish product manufacture and release of an intravenous formulation of PRP for clinical trials; and validate the ELISA assay for the analysis of PRP in human blood plasma to measure the distribution over time in patients. In addition, the Company expects to prepare and submit an investigational medicine product dossier (IMPD) and clinical trial application (CTA) for PRP in the UK, for FIM studies; as well as start FIM studies for PRP, targeting advanced cancer patients (solid tumors).
Propanc Health Group Corp. (PPCH), closed Wednesday's trading session at $0.012, up 10.09%, on 7,715,738 volume with 117 trades. The average volume for the last 60 days is 4,983,867 and the stock's 52-week low/high is $0.0067/$0.0516.
Concierge Technologies, Inc. (CNCG)
OnPointStockAlert, Penny Stock Prodigy, Penny Stock Titans, ProTrader, The Street, TopPennyStockMovers, Pumps and Dumps, Epic Stock Picks, EpicVIP Group, MomentumOTC, PennyStocks24, OTCPicks, Nebula Stocks, MicrocapVoice, and Light Speed Stocks reported on Concierge Technologies, Inc. (CNCG), and we also highlight the Company, here at the QualityStocks Daily Newsletter.
Concierge Technologies, Inc. operates via its wholly-owned subsidiary company Kahnalytics, Inc., and also operates via Brigadier Security Systems. Also, the Company acquired Gourmet Foods. Ltd. of Tauranga, New Zealand. The acquisition of Gourmet Foods completed on August 11, 2015. Concierge Technologies is headquartered in Valley Center, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Kahnalytics, Inc. is a U.S. based provider of live streaming mobile video, vehicle tracking and driver behavior data. Concierge Technologies founded Kahnalytics in June 2015. Kahnalytics has launched its online platform and has begun accepting subscribers to its service.
Gourmet Foods (started in 1966) is a well-established producer of popular New Zealand meat pies and bakery products under recognized supermarket brand names “Pat’s Pantry” and “Ponsonby Pies”. Gourmet Foods products are in convenience stores, major supermarkets, petrol stations, as well as restaurants. Gourmet Foods distributes greater than 30 products throughout New Zealand generating over 60,000 pieces weekly and growing.
Concierge Technologies has completed its enhanced production line facilities. The Company had advanced a loan of NZ$250,000 to Gourmet Foods reserved for acquisition of a high capacity packaging machine to accommodate expected production increases because of higher sales of its family-sized products to national grocery chains. The new machinery is installed.
On June 2, 2016, Concierge Technologies acquired Brigadier Security Systems of Saskatoon, Saskatchewan (an alarm installation and monitoring enterprise). Brigadier is a long-standing security alarm company serving the Province of Saskatchewan since 1985. Brigadier has security solutions ranging from products designed to protect residential premises and property through to complex access control and camera monitoring equipment.
Brigadier Security Systems designs customized solutions to meet clients' security needs in most all situations. Brigadier has offices in Saskatoon and Regina and is now among the largest independent security contractors in Saskatchewan.
Last month, Concierge Technologies announced the closing of the acquisition of Wainwright Holdings, Inc., a Delaware corporation, in a stock-for-stock exchange valued at roughly $85 million. Wainwright Holdings will continue to operate its businesses as a wholly-owned subsidiary of Concierge Technologies.
Concierge Technologies, Inc. (CNCG), closed Wednesday's trading session at $0.061, up 17.31%, on 500 volume with 1 trade. The average volume for the last 60 days is 19,089 and the stock's 52-week low/high is $0.02/$0.10.
Spotlight Innovation, Inc. (STLT)
Profitable Trader Authority, Damn Good Penny Picks, OTCtipReporter, Penny Picks, PennyStockScholar. Journal Transcript, PennyStockLocks, StockRockandRoll, Elite Stock Alerts, Journal Transcript, Beacon Equity Research, Penny Stock Finder, Stock Preacher, SuperStockTips, InvestorSoup, Penny Stock Craze, and Stock Commander reported on Spotlight Innovation, Inc. (STLT), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
A pharmaceutical company, Spotlight Innovation, Inc. advances technologies designed to address rare, emerging, and neglected diseases. The Company identifies and acquires rights to innovative and proprietary platform technology candidates. The Company’s focus is on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Spotlight Innovation is headquartered in Urbandale, Iowa.
Spotlight Innovation works to acquire the rights, through acquisition, license, or otherwise, to unique and proprietary Platform Technology Candidates. Furthermore, it works to provide value-added development capability and funding to realize quick IND approval to commence human clinicals for targeted Platform Technology Candidates.
The Company provides solutions for healthcare-focused companies commercializing healthcare intellectual property (IP). Spotlight will partner with proven market leaders through sale, out-license, or strategic alliance, when commercially significant benchmarks have been attained.
The Company’s mission is to greatly impact patient health through advancing new platform biotechnologies for cancer and infectious disease. Access to platform technology candidates is attained by way of its extensive relationships with numerous leading academic institutions and other sources. Spotlight provides value-added development capability and funding to hasten development progress.
Spotlight Innovation has retained distinguished French oncologist Mr. David Khayat, MD, PhD, FASCO, as the Principal Investigator for a European Phase I dose escalation safety study, “Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration.” The clinical study will take place at Pitié-Salpêtrière Hospital in Paris, France. Crotoxin is one of many proprietary compounds, owned by Spotlight Innovation, derived from snake venom.
Spotlight Innovation announced in October 2016 that it obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. The license is to commercialize STL-182. This is an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA).
Spotlight Innovation has obtained from the Florida State University Research Foundation exclusive global rights to develop and commercialize certain compounds for the treatment of viral infections. This includes the Zika virus infection. Included among the licensed compounds are those identified in a study co-authored by Florida State University Professor Hengli Tang published in Nature Medicine in August 2015. Prof. Tang and his research team collaborate with Spotlight Innovation as part of an existing sponsored research agreement (SRA). Prof. Tang is a member of Spotlight Innovation’s Scientific Advisory Board.
Today, Spotlight Innovation announced that subsidiary Caretta Therapeutics plans, in Q2 of this year, to launch its first product. Venodol. This is a topical roll-on intended to provide relief from chronic pain. Venodol is a non-addictive alternative to opioid and steroidal analgesics. It underwent development under a licensing agreement with Dr. Paul Reid to commercialize products derived from snake venom.
In addition, Caretta Therapeutics signed a Master Broker Agreement with a premier worldwide distribution brokerage firm to distribute its products into supermarket, drug store, mass merchandise, and warehouse chains.
Spotlight Innovation, Inc. (STLT), closed Wednesday's trading session at $0.71, up 2.90%, on 808,945 volume with 585 trades. The average volume for the last 60 days is 52,560 and the stock's 52-week low/high is $0.335/$1.75.
Cerebain Biotech Corp. (CBBT)
Viral Stocks, Wall Street Mover, and Greenbackers reported earlier on Cerebain Biotech Corp. (CBBT), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Cerebain Biotech Corp. centers on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. A development-stage medical device organization, the Company formerly went by the name Discount Dental Materials, Inc. It changed its corporate name to Cerebain Biotech Corp. in June 2014. Cerebain Biotech is headquartered in Costa Mesa, California.
The Company’s device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. Its patent-pending device is implanted in the omentum. This is a protective layer of skin that protects the abdominal organs. The design of the device is to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.
Cerebain Biotech’s technology has allowed for the development of a medical device that can be implanted using a minimally invasive procedure. Upon implantation, through what will most likely be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method. Cerebain has a manufacturing agreement with Sonos Medical, a medical device supplier.
Cerebain Biotech intends to seek Food and Drug Administration (FDA) approval in tandem with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. Cerebain has reached a decisive point in its research and is planning to commence development of the device.
Cerebain Biotech has signed a Memorandum of Understanding (MOU) with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the MOU is to begin testing of Cerebain Biotech’s Medical Device upon completion of development.
Current plans for Cerebain Biotech include allocating resources to facilitate its FDA strategy as it relates to further research and testing of the Company’s existing technology. Plans also include designing a surgical manual to be used by doctors and clinicians for implanting Cerebain’s medical device. Furthermore, the Company will provide additional administrative and financial support to its scientists to take advantage of their time to advance Cerebain’s technologies as it nears clinical trials.
Cerebain Biotech Corp. (CBBT), closed Wednesday's trading session at $0.318996, up 48.30%, on 900 volume with 5 trades. The average volume for the last 60 days is 1,262 and the stock's 52-week low/high is $0.2151/$1.75.
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.02263, up 13.15%, on 30,031,174 volume with 910 trades. The stock’s average daily volume over the past 60 days is 3,057,145, and its 52-week low/high is $0.0046/$0.0245.
Singlepoint, Inc. was highlighted today in an article by NetworkNewsWire on the rapid development of the sector-crucial marijuana banking issue, as new reforms are called for to assist dispensaries and other vendors when it comes to security, and general ease of payment processing.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
Mounting Support for Marijuana Banking Has Widespread Implications
Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry
SinglePoint Subsidiary: Opportunities High Amid Congressional Call for Cannabis Banking Reform
GainClients, Inc. (GCLT)
The QualityStocks Daily Newsletter would like to spotlight GainClients, Inc. (GCLT). Today, GainClients, Inc. closed trading at $0.033, even for the day, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 142,206, and its 52-week low/high is $0.01/$0.20.
GainClients, Inc. (GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company's innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data.
The company's main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions.
Similar to the features of other popular online networks, professional users can invite clients and their industry partners to join their GCard networks and be featured as trusted team members. From here, the teams can quickly provide real estate, lending and title services and information to consumers via smartphone and web. With better communication throughout the process of buying or selling homes, purchases can move more quickly and more comfortably to completion.
Strategic partnerships are an important component of GainClients' growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies' proprietary technologies to the real estate industry. CLOVIS will use GainClients' GCard to develop a unique lead generation program for the broader real estate marketing and advertising industry.
GainClients also offers GCHomeSearch, its stand-alone website that provides non-real estate customers, such as lenders and title professionals, with accurate listing data, historical property data, neighborhood information and demographics. When used with the GCard, the user is also privy to loan payment calculators, loan rates, closing cost estimators and other tools needed to make intelligent buying and selling choices. Disclaimer
GainClients, Inc. Company Blog
GainClients, Inc. News:
GainClients, Inc. Retains Largest Real Estate Customer on its GCard Service
GainClients, Inc. Announces Corporate Update
GainClients, Inc. Enters Into A Licensing Agreement with Real Estate Technology Upstart CLOVIS, LLC To Expand Its Technology Platform
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.50, off by 0.28%, on 12,014 volume with 18 trades. The stock’s average daily volume over the past 60 days is 10,834, and its 52-week low/high is $0.6101/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp Realty Nearly Triples Agent Count in 2016
eXp World Holdings, Inc. Announces Appointment of Independent Director
eXp World Holdings, Inc. Retains MZ Group as its Investor Relations Advisor
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.35, off by 5.62%, on 8,360 volume with 9 trades. The stock’s average daily volume over the past 60 days is 9,727, and its 52-week low/high is $1.10/$5.00.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Monaker Group Appoints Simon Orange to Board of Directors Appointment Advances Monaker's Plans for NASDAQ Listing
Monaker Group Shareholder Update -- 2016 Milestones and Transactional Business
Monaker Group (MKGI): Tip of the Travel Industry Iceberg -- SECFilings.com
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0011, off by 15.38%, on 26,730,799 volume with 53 trades. The stock’s average daily volume over the past 60 days is 16,721,731 and its 52-week low/high is $0.0009/$0.037.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Dominovas Energy Dispatches Watkins to Meet With Gas Supplier
Today's Top 3
The QualityStocks Public Company Sponsor News